QualityStocks would like to highlight Aethlon Medical, Inc. (OTCBB: AEMD), a development stage medical device company focused on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that removes viral pathogens, immunosuppressive glycoproteins, and exosomes from the circulatory system.
In the company’s news yesterday,
Aethlon Medical recently announced that Dr. Stephen Z. Fadem, a practicing Houston nephrologist, teacher, lecturer, and researcher, has agreed to join the company’s Extracorporeal Science Advisory Board. The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.
Dr. Fadem began his practice in 1978 after completing a renal fellowship at The University of Texas Health Science Center in San Antonio. He is also a graduate of the University of Oklahoma College of Medicine, and completed his internal medicine residency at The University of Texas and MD Anderson Hospital in Houston and is a Clinical Professor of Medicine, Baylor College of Medicine. Dr. Fadem is also a Fellow of the American College of Physicians, Fellow of the American Society of Nephrology, and diplomate of the American Board of Quality Assurance and Utilization Review Physicians.
In addition to his academic accomplishments within his field, Dr. Fadem has served as the Chairman of the National Kidney Foundation (NKF) of Southeast Texas Medical Advisory Board, and has received their Lifetime Achievement Award and the Myron L. Jenkins Award. He is the co-chairman of the Medical Advisory Board of the American Association of Kidney Patients (AAKP) and a past vice-president of the AAKP Board of Directors. He has also served on the Board of Directors of the Renal Physicians Association and actively serves on two national RPA committees, the Government Affairs Committee, and the Health Finance Committee. Dr. Fadem has been active in the Forum of ESRD Networks and was a member of the CMS Clinical Performance Measures Committee.
External to his field, Dr. Fadem is the founder of Touchcalc, a software design company, and serves as a consultant to the computer industry in the development of CKD management software. He serves as a lecturer on dialysis management, preventive nephrology, vascular calcification, anemia, patient education, CKD education, and computer technology and security. Dr. Fadem is the co-editor of AAKP Renalife and is a reviewer for several peer-reviewed journals.
Dr. Fadem has been nationally recognized, receiving the AAKP Nova Award, the NKF Distinguished Service Award. He has also received the NKF Presidents Award. He has been awarded the Peter Lundin Award for his contributions to patient education and The Visionary Award for his contributions to CKD education. He has also been named as one of America’s Top Doctors by Castle Connolly and US News and World Report.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
